医学
腺样囊性癌
阿西替尼
伦瓦提尼
临床试验
人口
肿瘤科
药品
靶向治疗
疾病
重症监护医学
内科学
舒尼替尼
癌
药理学
癌症
索拉非尼
肝细胞癌
环境卫生
作者
Vivian Petersen Wagner,Renata Ferrarotto,Pablo Agustín Vargas,Manoela Domingues Martins,Colin D. Bingle,Lynne Bingle
标识
DOI:10.1016/j.critrevonc.2022.103886
摘要
Adenoid cystic carcinoma (ACC) has a significant patient-population in need of effective systemic therapy, as no drug is currently approved by the FDA for its management. We critically reviewed ACC-clinical trials (CT) registered on the ClinicalTrials.gov website using "ACC" under condition or disease. Trials specifically designed to test a drug-based therapy for ACC (n = 33) were analyzed with most being one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Site restriction, maximum ECOG status, and period of disease progression varied as inclusion criteria. Small-molecule inhibitors were those most commonly investigated with Apatinib, Axitinib and Lenvatinib showing the best results in association with rigid enrollment criteria. The overall median time to progression remains modest and more efforts are urgently needed in this field. CTs designed to test drugs that act on key pathways associated with ACC aggressiveness are being conducted and represent a promising pathway if efficacy is proved.
科研通智能强力驱动
Strongly Powered by AbleSci AI